Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced today that CEO Masoud Tavazoie, M.D., Ph.D., will present at the Stifel 2021 Virtual Healthcare Conference at 10:40 A.M. EST on November 17, 2021.

To view this virtual presentation, live, register for the event here.

Links to the live and archived version of this presentation will also be available on Inspirna’s website within the News section.

About Inspirna

Inspirna, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancer progression. The company is pursuing several first-in-class drug candidates to treat cancers of high unmet need. Inspirna identifies novel cancer targets using its RNA-based target discovery platform, RNA-DRIVErTM, which was originally developed by Inspirna’s scientific co-founders at The Rockefeller University and exclusively licensed to Inspirna. The Company brings together distinguished scientific founders, a seasoned board of directors, and a leadership team comprised of experienced drug developers. The Company is funded by leading biotechnology investors, including Novo Holdings A/S, Sofinnova Partners, Lepu Holdings Limited, Sixty Degree Capital, K2 HealthVentures, Oceanpine Capital, WuXi PharmaTech Healthcare Fund I, LP, Alexandria Venture Investments, LLC, Exor Seeds, and the Partnership Fund for New York City. For more information, please visit www.inspirna.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005352/en/